Identification of Predictors for Treatment Failure in Hepatitis C Virus Patients Treated With Ledipasvir and Sofosbuvir.

about

Identification of Predictors for Treatment Failure in Hepatitis C Virus Patients Treated With Ledipasvir and Sofosbuvir.

Item

http://www.wikidata.org/entity/Q40338014

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Identification of Predictors f ...... ith Ledipasvir and Sofosbuvir.

@en

type

Item

label

Identification of Predictors f ...... ith Ledipasvir and Sofosbuvir.

@en

prefLabel

Identification of Predictors f ...... ith Ledipasvir and Sofosbuvir.

@en

P1476

Identification of Predictors f ...... ith Ledipasvir and Sofosbuvir.

@en

P2093

Gillian M Powderly

http://www.w3.org/2001/XMLSchema#string

Jeffrey W Jansen

http://www.w3.org/2001/XMLSchema#string

Travis W Linneman

http://www.w3.org/2001/XMLSchema#string

P2860

Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

Boceprevir for previously treated chronic HCV genotype 1 infection

Global epidemiology and genotype distribution of the hepatitis C virus infection

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.

Response-guided telaprevir combination treatment for hepatitis C virus infection

Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12.

P304

543-547

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1060028017693348

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28193102

http://www.w3.org/2001/XMLSchema#string

P921

sofosbuvir